Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...
Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results